Nowadays, an approach based on adipose-derived stem cells (ADSCs) injection allows to maintain the breast volume achieved after fat grafting. The first ever evidences of ADSCs advantages come from the 16^th Annual IFATS Meeting organized by the International Federation for Adipose Therapeutics and Science in Las Vegas (USA), where Bioscience Institute presented the results of a 4-years follow-up of patients subjected to autologous expanded ADSCs implant for breast augmentation.

Breast volume MRI analysis was performed under the medical supervision of Bioscience Institute medical director, Roberto Viel, before and 4 years after ADSCs treatment, revealing that appropriate injection allows to maintain 100% of the volume achieved with fat grafting. When patient BMI increased, total breast volume increased too, reaching 109 to 135% of total breast volume achieved with fat injection, demonstrating fat graft behaves like fat in other parts of the organism.

Such results have been made possible by Liposkill Plus, a body shaping approach based on expansion of autologous ADSCs to be injected in patient's breast to obtain a double aesthetic goal: improving breast volume without breast implants and eventually removing fat from undesired deposits (e.g. abdomen, tights).

ADSCs expansion is fundamental for long-lasting results, allowing to get the minimum right dose of cells for injection (100-150 thousand cells/ml of fat for a volume between 400 to 800 ml).